303 related articles for article (PubMed ID: 33500259)
1. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
[TBL] [Abstract][Full Text] [Related]
2. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
4. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
[TBL] [Abstract][Full Text] [Related]
5. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
6. A new oncolytic
Ahmed J; Chard LS; Yuan M; Wang J; Howells A; Li Y; Li H; Zhang Z; Lu S; Gao D; Wang P; Chu Y; Al Yaghchi C; Schwartz J; Alusi G; Lemoine N; Wang Y
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217766
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
11. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Inoue T; Byrne T; Inoue M; Tait ME; Wall P; Wang A; Dermyer MR; Laklai H; Binder JJ; Lees C; Hollingsworth R; Maruri-Avidal L; Kirn DH; McDonald DM
Mol Cancer Ther; 2021 Aug; 20(8):1481-1494. PubMed ID: 34045231
[TBL] [Abstract][Full Text] [Related]
12. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer.
Chard LS; Maniati E; Wang P; Zhang Z; Gao D; Wang J; Cao F; Ahmed J; El Khouri M; Hughes J; Wang S; Li X; Denes B; Fodor I; Hagemann T; Lemoine NR; Wang Y
Clin Cancer Res; 2015 Jan; 21(2):405-16. PubMed ID: 25416195
[TBL] [Abstract][Full Text] [Related]
13. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
14. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
15. Transient inhibition of neutrophil functions enhances the antitumor effect of intravenously delivered oncolytic vaccinia virus.
Zhou D; Xu W; Ding X; Guo H; Wang J; Zhao G; Zhang C; Zhang Z; Wang Z; Wang P; Lu L; Yuan M
Cancer Sci; 2024 Apr; 115(4):1129-1140. PubMed ID: 38351514
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
18. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.
Chen W; Fan W; Ru G; Huang F; Lu X; Zhang X; Mou X; Wang S
Oncol Rep; 2019 Jan; 41(1):67-76. PubMed ID: 30365143
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
